US › Healthcare

Anixa Biosciences Inc (ANIX)

US · Healthcare · Biotechnology

$2.76+6.15%

Last close · 2026-09-17

Latest quarter · ended 2026-07-31

Revenue

Net profit

$-2.6M

EPS

$-0.08

EPS estimate

$-0.08

EPS came in at -0.08 against a street estimate of -0.08 — a beat of 0.0%.

Key statistics

Market cap

$90.4M

Forward P/E

0.0

P/B

6.46

Book value

$0.46

EPS (TTM)

$-0.32

52-week high

$5.46

52-week low

$2.32

50-day MA

$3.31

200-day MA

$3.11

Beta

0.52

Analyst view

Analysts rate Anixa Biosciences Inc a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $10.00.

Shareholding

Insiders

5.50%

Institutions

14.16%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.87%
Laird Norton Tyee Trust Co	1.66%
UBS Group AG	1.62%
Davidson D A & Co	1.58%
Geode Capital Management, LLC	1.07%
Vanguard Fiduciary Trust Co	0.56%
Marshall Wace Asset Management Ltd	0.51%
BlackRock Inc	0.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Anixa Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.